Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BioGeneration Ventures (BGV) is a venture capital firm founded in 2006 and headquartered in Naarden, The Netherlands. The firm focuses on seed investments in innovative early-stage companies within the life sciences sector, particularly biotechnology. BGV is recognized as a leading European seed-stage life sciences VC, managing over €440 million across five funds. The firm has established a strong reputation for its commitment to scientific breakthroughs that address high unmet medical needs.
BGV has achieved notable milestones, including the successful exit of Acerta Pharma, which was sold to AstraZeneca for up to $7 billion in 2016. This exit is considered one of the most significant in European biotech history. The firm operates primarily in North America and Europe, establishing strategic partnerships with healthcare companies and academic institutions to enhance its investment capabilities.
BGV primarily invests in early-stage biotech companies that are developing solutions for high unmet medical needs. The firm generally acts as the lead investor and focuses on sectors such as oncology, central nervous system (CNS) disorders, rare diseases, metabolic disorders, autoimmune diseases, and ophthalmology. BGV's investment strategy emphasizes scientific breakthroughs with demonstrable proof of concept, ensuring that the companies it supports have a solid foundation for growth.
The firm typically invests between €100,000 and €1 million, with a sweet spot around €500,000. BGV often co-invests or transitions portfolio companies to larger follow-on funds, such as Forbion's Formation strategy, to provide continued support as companies scale. This approach allows BGV to maintain a strong presence in the life sciences sector while fostering innovation and collaboration.
BGV's portfolio includes a diverse range of companies focused on addressing critical medical needs. Notable portfolio companies include:
BGV has also achieved notable exits, including Acerta Pharma, which developed the FDA-approved drug Calquence® and was sold to AstraZeneca for up to $7 billion, and Synaffix, which was acquired by Lonza for €160 million in 2023.
Edward van Wezel: Managing Partner with extensive experience in venture capital and a background in life sciences. He has led numerous successful investments in the biotech sector.
Oskar Slotboom: Managing Partner who has been with BGV since its inception. He has a strong commercial and business development background, contributing to the firm's strategic direction.
Daniela Couto, PhD: General Partner with a focus on scientific evaluation and due diligence. She has a strong academic background and experience in biotech investments.
Keno Gutierrez, PhD: General Partner specializing in early-stage biotech investments. He has a background in research and development, providing valuable insights into portfolio companies.
Rianne Ellenbroek, PhD: Principal who works across all BGV funds, focusing on deal sourcing and portfolio management. She has a strong background in life sciences and venture capital.
Wouter Verhoeven: Venture Partner and CEO at Dualyx, providing operational expertise and strategic guidance to portfolio companies.
Rob de Ree: Venture Partner with experience in board management and interim roles at portfolio companies, ensuring effective governance and support.
Elena Ritsou, PhD: Venture Partner with a focus on scientific evaluation and investment strategy, contributing to BGV's rigorous selection process.
To pitch to BGV, startups should submit their proposals through the firm's website or via email at info@biogeneration.vc. A comprehensive pitch deck is essential, including information about the team, technology, market opportunity, and financial projections. BGV prefers to receive pitches that are concise and focused, allowing for a clear understanding of the startup's value proposition.
Response times can vary, but founders should expect to hear back within a few weeks. Warm introductions are beneficial and can enhance the likelihood of a favorable response.
BGV operates the FIRST Fund (Fonds InvesteringsRijpe Starters), which finances pioneering scientists in the Netherlands focusing on regenerative medicine and cardiovascular diseases. This fund supports scientists in transforming discoveries into sustainable companies.
In July 2023, BGV closed its fifth fund, BGV Fund V, at €150 million, marking its largest fund to date. This fund will continue to support early-stage biotech and medtech investments across Europe.
In March 2026, BGV announced the first closing of the FIRST II fund at €12 million, targeting very early-stage European life sciences companies. This fund aims to finance pioneering scientists focusing on regenerative medicine and cardiovascular diseases.
BGV has been actively involved in the life sciences sector, collaborating with other investors and academic institutions to foster innovation and support portfolio companies.
What are BGV's investment criteria?
BGV primarily invests in early-stage biotech companies that address high unmet medical needs. The firm focuses on sectors such as oncology, CNS disorders, rare diseases, metabolic disorders, autoimmune diseases, and ophthalmology.
How can startups apply or pitch to BGV?
Startups can pitch to BGV by submitting their proposals through the firm's website or by contacting them directly via email at info@biogeneration.vc. A well-prepared pitch deck should include details about the team, technology, market opportunity, and financial projections.
What makes BGV different from other venture capital firms?
BGV distinguishes itself through its focus on seed-stage investments in the life sciences sector and its strong network of industry experts. The firm often acts as the lead investor and provides strategic guidance to its portfolio companies.
What is BGV's geographic scope?
BGV operates primarily in North America and Europe, establishing partnerships with healthcare companies and academic institutions in these regions to enhance its investment capabilities.
What is BGV's typical fund size and check size?
BGV manages over €440 million across five funds, with typical check sizes ranging from €100,000 to €1 million, and a sweet spot around €500,000.
What kind of post-investment involvement does BGV have?
BGV provides ongoing support to its portfolio companies through strategic guidance, access to a network of industry experts, and often co-invests or transitions companies to larger follow-on funds for continued growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.